<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>ACTC.OB investor blog</title>
	<link>http://www.actcblog.com</link>
	<description>Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotechnology company applying cellular technology in the field of regenerative medicine.</description>
	<lastBuildDate>Tue, 24 Jan 2012 04:09:17 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.0" -->

	<item>
		<title>ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients</title>
		<description><![CDATA[Study in The Lancet Shows No Safety Concerns and Improved Vision in Patients with Macular Degeneration
MARLBOROUGH, Mass. — Jan. 23, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet  as an early online publication demonstrate [...]]]></description>
		<link>http://www.actcblog.com/2012/01/first-report-of-embryonic-stem-cell-esc-derived-cells-transplanted-into-patients.html</link>
			</item>
	<item>
		<title>Scientific Luminary Dr. Robert Langer Joins ACT’s Board of Directors</title>
		<description><![CDATA[World-renowned scientist and youngest member ever elected to all three U.S. National Academies; Also named One of the 100 Most Important People in America by Time Magazine and CNN
MARLBOROUGH, Mass. — October 5, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Robert S. [...]]]></description>
		<link>http://www.actcblog.com/2011/10/scientific-luminary-dr-robert-langer-joins-act%e2%80%99s-board-of-directors.html</link>
			</item>
	<item>
		<title>ACT and Roslin Cells Announce Collaboration for Storage and Distribution of Embryonic Stem Cells Using ACT&#8217;s Blastomere Technology</title>
		<description><![CDATA[The company issued the following announcement this morning.
ACT and Roslin Cells Announce Collaboration for Storage and Distribution of Embryonic Stem Cells Using ACT’s Blastomere Technology
 
Embryonic Stem Cells Made Using ACT’s Patented Technique Soon To Be Available for Researchers and Companies Worldwide
MARLBOROUGH, Mass.&#8211; June 21, 2011 &#8212; Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a [...]]]></description>
		<link>http://www.actcblog.com/2011/06/act-and-roslin-cells-announce-collaboration-for-storage-and-distribution-of-embryonic-stem-cells-using-act%e2%80%99s-blastomere-technology.html</link>
			</item>
	<item>
		<title>ACT Announces Oregon Health &amp; Science University As Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration</title>
		<description><![CDATA[The company issued the following release today.
ACT Announces Oregon Health &#38; Science University As Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
Institutional Review Board (IRB) Approves Phase 1/2 Trial for Stargardt’s Macular Dystrophy (SMD)
MARLBOROUGH, Mass. — May 16, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), [...]]]></description>
		<link>http://www.actcblog.com/2011/05/act-announces-oregon-health-science-university-as-clinical-trial-site-for-its-phase-12-clinical-trial-using-hesc-derived-rpe-cells-for-macular-degeneration.html</link>
			</item>
	<item>
		<title>Advanced Cell Technology Announces 2011 First Quarter Results</title>
		<description><![CDATA[The company issued the following release today.
Advanced Cell Technology Announces 2011 First Quarter Results
MARLBOROUGH, Mass. — May 9, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations [...]]]></description>
		<link>http://www.actcblog.com/2011/05/advanced-cell-technology-announces-2011-first-quarter-results.html</link>
			</item>
	<item>
		<title>ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells &amp; Regenerative Medicine Congress in London</title>
		<description><![CDATA[The company issued the following release today.
ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells &#38; Regenerative Medicine Congress in London
Mr. Rabin Will Discuss Two Upcoming Clinical Trials Using Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelial (RPE) Cells to Treat Macular Degeneration
MARLBOROUGH, Mass. — May 5, 2011 – Advanced Cell [...]]]></description>
		<link>http://www.actcblog.com/2011/05/235.html</link>
			</item>
	<item>
		<title>Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research</title>
		<description><![CDATA[The company issued the following press release today.
Advanced Cell Technology Praises Federal Appeals Court Ruling Allowing for Continued Federal Funding of Embryonic Stem Cell Research
Ruling Could Provide Tremendous Boost to Regenerative Medicine Industry
MARLBOROUGH, Mass. — May 2, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today [...]]]></description>
		<link>http://www.actcblog.com/2011/05/advanced-cell-technology-praises-federal-appeals-court-ruling-allowing-for-continued-federal-funding-of-embryonic-stem-cell-research.html</link>
			</item>
	<item>
		<title>ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration</title>
		<description><![CDATA[The company issued the following press release today.
UCLA’s Jules Stein Eye Institute to be a Site for Phase 1/2 Trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Dystrophy (Dry AMD) 
MARLBOROUGH, Mass. – April 28, 2011 &#8211; Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced [...]]]></description>
		<link>http://www.actcblog.com/2011/04/act-announces-ucla-institutional-review-board-irb-approval-of-its-phase-12-clinical-trials-using-hesc-derived-rpe-cells-for-the-treatment-of-macular-degeneration.html</link>
			</item>
	<item>
		<title>Reuters interviews ACT&#8217;s Dr. Robert Lanza: Embryonic stem cells still &#8220;gold standard&#8221;</title>
		<description><![CDATA[Following are excerpts from a Reuters story that ran on March 31, 2011; it includes quotes from an interview with ACT&#8217;s Chief Scientific Officer, Dr. Robert Lanza.  
The original article may be found here.
ANALYSIS-Imperfections mar hopes for reprogrammed stem cells
31 Mar 2011 19:12
Source: Reuters // Reuters
* Reprogrammed stem cells rife with mutations, problems
* Embryonic [...]]]></description>
		<link>http://www.actcblog.com/2011/04/reuters-interviews-acts-dr-robert-lanza-embryonic-stem-cells-still-gold-standard.html</link>
			</item>
	<item>
		<title>ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China</title>
		<description><![CDATA[The Company issued the following announcement this morning.
ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
Chinese Patent to Cover Fundamental Methods for Producing Retinal Pigment Epithelial (RPE) Cells from Embryonic Stem Cells and Therapeutic Formulations for Treating Patients with Retinal Degenerative Diseases
MARLBOROUGH, Mass. – March 23, 2011 &#8211; Advanced Cell [...]]]></description>
		<link>http://www.actcblog.com/2011/03/act-to-be-issued-broad-patent-for-human-es-cell-derived-rpe-cells-in-china.html</link>
			</item>
</channel>
</rss>

